OBJECTIVE: To assess the problem of multidrug-resistant tuberculosis (MDR-TB) throughout Belarus and investigate the associated risk factors. METHODS: In a nationwide survey in 2010-2011, 1420 tuberculosis (TB) patients were screened and 934 new and 410 previously treated cases of TB were found to meet the inclusion criteria. Isolates of Mycobacterium tuberculosis from each eligible patient were tested for susceptibility to anti-TB drugs. Sociobehavioural information was gathered in interviews based on a structured questionnaire. FINDINGS: MDR-TB was found in 32.3% and 75.6% of the new and previously treated patients, respectively, and, 11.9% of the 612 patients found to have MDR-TB had extensively drug-resistant TB (XDR-TB). A history of previous treatment for TB was the strongest independent risk factor for MDR-TB (odds ratio, OR: 6.1; 95% confidence interval, CI: 4.8-7.7). The other independent risk factors were human immunodeficiency virus (HIV) infection (OR: 2.2; 95% CI: 1.4-3.5), age < 35 years (OR: 1.4; 95% CI: 1.0-1.8), history of imprisonment (OR: 1.5; 95% CI: 1.1-2.0), disability sufficient to prevent work (OR: 1.9; 95% CI: 1.2-3.0), alcohol abuse (OR: 1.3; 95% CI: 1.0-1.8) and smoking (OR: 1.5; 95% CI: 1.1-2.0). CONCLUSION: MDR-TB is very common among TB patients throughout Belarus. The numerous risk factors identified for MDR-TB and the convergence of the epidemics of MDR-TB and HIV infection call not only for stronger collaboration between TB and HIV control programmes, but also for the implementation of innovative measures to accelerate the detection of TB resistance and improve treatment adherence.
OBJECTIVE: To assess the problem of multidrug-resistant tuberculosis (MDR-TB) throughout Belarus and investigate the associated risk factors. METHODS: In a nationwide survey in 2010-2011, 1420 tuberculosis (TB) patients were screened and 934 new and 410 previously treated cases of TB were found to meet the inclusion criteria. Isolates of Mycobacterium tuberculosis from each eligible patient were tested for susceptibility to anti-TB drugs. Sociobehavioural information was gathered in interviews based on a structured questionnaire. FINDINGS: MDR-TB was found in 32.3% and 75.6% of the new and previously treated patients, respectively, and, 11.9% of the 612 patients found to have MDR-TB had extensively drug-resistant TB (XDR-TB). A history of previous treatment for TB was the strongest independent risk factor for MDR-TB (odds ratio, OR: 6.1; 95% confidence interval, CI: 4.8-7.7). The other independent risk factors were human immunodeficiency virus (HIV) infection (OR: 2.2; 95% CI: 1.4-3.5), age < 35 years (OR: 1.4; 95% CI: 1.0-1.8), history of imprisonment (OR: 1.5; 95% CI: 1.1-2.0), disability sufficient to prevent work (OR: 1.9; 95% CI: 1.2-3.0), alcohol abuse (OR: 1.3; 95% CI: 1.0-1.8) and smoking (OR: 1.5; 95% CI: 1.1-2.0). CONCLUSION: MDR-TB is very common among TB patients throughout Belarus. The numerous risk factors identified for MDR-TB and the convergence of the epidemics of MDR-TB and HIV infection call not only for stronger collaboration between TB and HIV control programmes, but also for the implementation of innovative measures to accelerate the detection of TB resistance and improve treatment adherence.
Authors: Jürgen Rehm; Andriy V Samokhvalov; Manuela G Neuman; Robin Room; Charles Parry; Knut Lönnroth; Jayadeep Patra; Vladimir Poznyak; Svetlana Popova Journal: BMC Public Health Date: 2009-12-05 Impact factor: 3.295
Authors: Shelly F Greenfield; Alan Shields; Hilary Smith Connery; Viktoriya Livchits; Sergey A Yanov; Charmaine S Lastimoso; Aivar K Strelis; Sergey P Mishustin; Garrett Fitzmaurice; Trini A Mathew; Sonya Shin Journal: Alcohol Clin Exp Res Date: 2009-11-20 Impact factor: 3.455
Authors: Knut Lönnroth; Ernesto Jaramillo; Brian G Williams; Christopher Dye; Mario Raviglione Journal: Soc Sci Med Date: 2009-04-23 Impact factor: 4.634
Authors: Trini A Mathew; Sergey A Yanov; Rais Mazitov; Sergey P Mishustin; Aivar K Strelis; Galina V Yanova; Vera T Golubchikova; Dmitry V Taran; Alex Golubkov; Alan L Shields; Shelly F Greenfield; Sonya S Shin Journal: Eur J Public Health Date: 2008-12-26 Impact factor: 3.367
Authors: Knut Lönnroth; Brian G Williams; Stephanie Stadlin; Ernesto Jaramillo; Christopher Dye Journal: BMC Public Health Date: 2008-08-14 Impact factor: 3.295
Authors: Natasha Van't Boveneind-Vrubleuskaya; Tatiana Seuruk; Kai van Hateren; Tridia van der Laan; Jos G W Kosterink; Tjip S van der Werf; Dick van Soolingen; Susan van den Hof; Alena Skrahina; Jan-Willem C Alffenaar Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren Journal: Lancet Respir Med Date: 2014-03-24 Impact factor: 30.700
Authors: Ruthie B Birger; Roger D Kouyos; C Jessica E Metcalf; Ted Cohen; Emily C Griffiths; Silvie Huijben; Michael J Mina; Victoriya Volkova; Bryan Grenfell Journal: Trends Microbiol Date: 2015-05-29 Impact factor: 17.079
Authors: M Mansfeld; A Skrahina; L Shepherd; A Schultze; A M Panteleev; R F Miller; J M Miro; I Zeltina; S Tetradov; H Furrer; O Kirk; A Grzeszczuk; N Bolokadze; A Matteelli; F A Post; J D Lundgren; A Mocroft; Amw Efsen; D N Podlekareva Journal: HIV Med Date: 2015-05-11 Impact factor: 3.180
Authors: A M W Efsen; A Schultze; R F Miller; A Panteleev; A Skrahin; D N Podlekareva; J M Miro; E Girardi; H Furrer; M H Losso; J Toibaro; J A Caylà; A Mocroft; J D Lundgren; F A Post; O Kirk Journal: J Infect Date: 2017-10-20 Impact factor: 6.072
Authors: V Rusovich; A M V Kumar; A Skrahina; H Hurevich; A Astrauko; P de Colombani; K Tayler-Smith; M Dara; R Zachariah Journal: Public Health Action Date: 2014-12-21
Authors: D Klimuk; H Hurevich; A D Harries; A Babrukevich; K Kremer; R Van den Bergh; C D Acosta; A Astrauko; A Skrahina Journal: Public Health Action Date: 2014-10-21